By Nina Lapke, Biomedical Informatics Scientist of ACT Genomics
Tissue-agnostic drug is a new way to treat cancer via biomarkers across tumor types, which brings precision medicine one step further to treat more patients properly. With clinical trials combining patients of various cancer types according to their tumo
By By Dr. Song Ling Poon, Senior Medical Science Liaison of ACT Genomics
Tumor mutational burden (TMB) has emerged as an important biomarker for predicting response for immune checkpoint inhibitors. What are the challenges currently faced by TMB and what is being done to address these issues?
© 2019 Todsyshealth. All rights reserved.